Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42257650.
- Also identified by DOI 10.2337/dc26-0567.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated whether fasting 2-hydroxybutyrate (2-HB), measured by a novel enzymatic assay (XpressGT), can provide incremental discrimination of dysglycemia beyond routine fasting measures. Associations of 2-HB with dysglycemia were assessed in the total Biomarkers of Personalized Medicine cohort and in the prespecified subcohort with fasting plasma glucose (FPG) <110 mg/dL and HbA1c <39 mmol/mol (5.7%). Among 772 individuals, 2-HB increased from normoglycemia (39.0 µmol/L) to prediabetes (51.9 µmol/L) and type 2 diabetes (57.0 µmol/L). In 534 individuals with normal FPG and HbA1c, 2-HB yielded the area under the receiver operating characteristic curve of 0.79 for postprandial dysglycemia (2-h glucose >140 mg/dL during oral glucose tolerance testing). A sensitivity of 90% was achieved at 39 µmol/L, with a negative predictive value of 98.9%. Each 1-SD increase in 2-HB was independently associated with dysglycemia (odds ratio 2.23; P < 0.001). Enzymatic 2-HB measurement may serve as a screening biomarker to rule out postprandial dysglycemia in individuals with normal FPG and HbA1c.